Where is Hycon located?

Hycon is headquartered in Hauppauge, United States.

Is Hycon a funded company?

Hycon is a funded company, having raised a total of $***** in its 1st and only funding round.

Where does Hycon rank among its competitors?

Hycon ranks 379th amongst 372 active competitors, of which 15 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was PCI, which secured an undisclosed amount in Jul, 2025.

Who are the top competitors of Hycon?

Hycon's top competitors include Concord Biotech, Aizant and Almac Group. Among them, PCI secured the most recent funding round in July, 2025.

Hycon - 2026 Company Profile & Competitors

Hycon is an unfunded company based in Hauppauge (United States), founded in 2023. It operates as a CDMO providing formulation, analytical, manufacturing, packaging, and regulatory services for pharmaceutical products. Hycon has not raised any funding yet. The company has 372 active competitors, including 15 funded and 91 that have exited. Its top competitors include companies like Concord Biotech, Aizant and Almac Group.

Company Details

CDMO providing formulation, analytical, manufacturing, packaging, and regulatory services for pharmaceutical products. It offers product development, preformulation studies, analytical method development, stability testing, and polymorph screening. It provides IND enabling and GLP toxicology studies, targeting therapeutic areas like orphan diseases, oncology, CNS, cardiometabolic diseases, and pediatrics. Processing technologies include spray drying, Wurster fluid bed coating, hot melt extrusion, micronization, and particle engineering. It supports clinical trials with manufacturing solutions for preclinical through Phase 3, comparator sourcing, direct-to-patient services, clinical returns, and packaging. It handles pharmaceutical manufacturing, commercial manufacturing, over-the-counter products, technology transfers, high potent APIs, and scheduled substances. Dosage forms include oral, semi-solids, injectables, topicals, ophthalmic, and inhalables, utilizing formulation technologies for bioavailability enhancement, lipid nanoparticles, and controlled release.

Key Metrics

Founded Year

2023

Location

Hauppauge, United States

Stage

Unfunded

Ranked

379^th among 419 competitors

Similar Companies

Concord Biotech & 417 more

View Hycon's full profile

Hycon has not raised any funding rounds yet.

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Hycon include Concord Biotech, Aizant and Almac Group. Here is the list of Top 10 competitors of Hycon, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Concord Biotech 2000, Ahmedabad (India), Public	CDMO focused on manufacturing API	-	Quadria Capital, Helix Investments & 18 others	65/100
2nd	Aizant 2005, Hyderabad (India), Series A	Company offering contract development services for small molecules	$16.8M	Zephyr Management, Zephyr Peacock & 39 others	60/100
3rd	Almac Group 2001, Craigavon (United Kingdom), Series D	CRAMS company offering preclinical development and CDMO services, also offering companion diagnostic development	$339M	Genomic Health, Europa & 4 others	57/100
4th	Nucleus RadioPharma 2022, Rochester (United States), Series A	CDMO focused on providing of radiopharmaceuticals manufacturing and supply chain services	$72.1M	Eclipse, AstraZeneca & 7 others	54/100
5th	Indoco Remedies 1947, Mumbai (India), Public	Provider of APIs manufacturing and formulation services	-	Baring Private Equity Partners	54/100
6th	Wanbury Limited 1990, Mumbai (India), Public	Manufacturer of anti-diabetic drugs	-	-	53/100
7th	Biophore 2007, Hyderabad (India), Seed	Development and manufacturing of niche pharmaceutical products for the generic industry	$2.74M	Ontario & 6 others	52/100
8th	Galenicum 2003, Barcelona (Spain), Late Stage	Turnkey solutions for drug development, manufacturing and regulatory approvals	-	Peninsula Capital	52/100
9th	Aptuit 2004, Greenwich (United States), Acquired	Pioneering drug discovery and development, accelerating concept to cure	$14.2M	Temasek, Europa & 1 others	50/100
10th	PCI 1997, Philadelphia (United States), Late Stage	Provider of clinical & commercial supply chain and packaging solutions	-	Bain Capital, Frazier Healthcare Partners ... & 7 others	50/100
379th	Hycon 2023, Hauppauge (United States), Unfunded	CDMO providing formulation, analytical, manufacturing, packaging, and regulatory services for pharmaceutical products	-	-	16/100